Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system

BackgroundAmlodipine, a widely prescribed clinical medication, is associated with adverse reactions that can impede the proper execution of treatment regimens. The lack of systematic studies on amlodipine's adverse drug reactions (ADRs) necessitates further investigation to facilitate refined p...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiazhen Jiang, Qian Zhong, Xinyu Zhou, Lisi Zhou, Jiyuan Zheng, Bingshuo Liu, Xingwei Di
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2025.1504671/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849431179484200960
author Jiazhen Jiang
Qian Zhong
Xinyu Zhou
Lisi Zhou
Jiyuan Zheng
Bingshuo Liu
Xingwei Di
author_facet Jiazhen Jiang
Qian Zhong
Xinyu Zhou
Lisi Zhou
Jiyuan Zheng
Bingshuo Liu
Xingwei Di
author_sort Jiazhen Jiang
collection DOAJ
description BackgroundAmlodipine, a widely prescribed clinical medication, is associated with adverse reactions that can impede the proper execution of treatment regimens. The lack of systematic studies on amlodipine's adverse drug reactions (ADRs) necessitates further investigation to facilitate refined population management and optimize therapeutic outcomes.MethodThis study leveraged the FDA Adverse Event Reporting System (FAERS) database, extracting reports submitted exclusively by healthcare professionals where amlodipine was designated as the primary suspect (PS). Four risk signal detection methods were employed: Ratio of Odds Ratio, Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, and Empirical Bayes Geometric Mean, to conduct a comprehensive analysis of amlodipine-related ADRs. Furthermore, subgroup analyses stratified by gender and age were performed, with multivariable logistic regression utilized to validate the reliability of the findings.ResultsAcross the general population, male cohort, female cohort, elderly group, and younger demographic, the four signal detection methods collectively identified 513, 348, 403, 246, and 260 potential ADRs associated with amlodipine, respectively. Intersection analysis revealed 27 common ADRs, including gingival hypertrophy, vasoplegia syndrome, and distributive shock. Subsequent multivariable logistic regression confirmed amlodipine's role as an independent risk factor for all 27 ADRs (OR > 1, P < 0.05).ConclusionThis study provides compelling evidence that amlodipine poses risks of peripheral edema, shock, and dyspnea, among others. Additionally, it identified previously unreported ADRs such as abnormal full blood count and personality disorder. These findings underscore the importance of exercising caution when prescribing amlodipine to high-risk individuals with a history of hyperkalemia, cardiac structural abnormalities, or airway obstruction.
format Article
id doaj-art-3598cb3262f347beb2c4d4e537495f4d
institution Kabale University
issn 2297-055X
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cardiovascular Medicine
spelling doaj-art-3598cb3262f347beb2c4d4e537495f4d2025-08-20T03:27:43ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-05-011210.3389/fcvm.2025.15046711504671Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting systemJiazhen Jiang0Qian Zhong1Xinyu Zhou2Lisi Zhou3Jiyuan Zheng4Bingshuo Liu5Xingwei Di6The First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaDepartment of Cardiovascular Medicine, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, ChinaThe First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaClinical Medical College of Acupuncture, Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaThe First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaThe Fifth Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaDepartment of Cardiovascular Medicine, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaBackgroundAmlodipine, a widely prescribed clinical medication, is associated with adverse reactions that can impede the proper execution of treatment regimens. The lack of systematic studies on amlodipine's adverse drug reactions (ADRs) necessitates further investigation to facilitate refined population management and optimize therapeutic outcomes.MethodThis study leveraged the FDA Adverse Event Reporting System (FAERS) database, extracting reports submitted exclusively by healthcare professionals where amlodipine was designated as the primary suspect (PS). Four risk signal detection methods were employed: Ratio of Odds Ratio, Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, and Empirical Bayes Geometric Mean, to conduct a comprehensive analysis of amlodipine-related ADRs. Furthermore, subgroup analyses stratified by gender and age were performed, with multivariable logistic regression utilized to validate the reliability of the findings.ResultsAcross the general population, male cohort, female cohort, elderly group, and younger demographic, the four signal detection methods collectively identified 513, 348, 403, 246, and 260 potential ADRs associated with amlodipine, respectively. Intersection analysis revealed 27 common ADRs, including gingival hypertrophy, vasoplegia syndrome, and distributive shock. Subsequent multivariable logistic regression confirmed amlodipine's role as an independent risk factor for all 27 ADRs (OR > 1, P < 0.05).ConclusionThis study provides compelling evidence that amlodipine poses risks of peripheral edema, shock, and dyspnea, among others. Additionally, it identified previously unreported ADRs such as abnormal full blood count and personality disorder. These findings underscore the importance of exercising caution when prescribing amlodipine to high-risk individuals with a history of hyperkalemia, cardiac structural abnormalities, or airway obstruction.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1504671/fullamlodipineadverse drug reactionsFDA adverse event reporting systemrisk signal detectionlogistic regression
spellingShingle Jiazhen Jiang
Qian Zhong
Xinyu Zhou
Lisi Zhou
Jiyuan Zheng
Bingshuo Liu
Xingwei Di
Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
Frontiers in Cardiovascular Medicine
amlodipine
adverse drug reactions
FDA adverse event reporting system
risk signal detection
logistic regression
title Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
title_full Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
title_fullStr Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
title_full_unstemmed Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
title_short Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
title_sort adverse events associated with amlodipine a pharmacovigilance study using the fda adverse event reporting system
topic amlodipine
adverse drug reactions
FDA adverse event reporting system
risk signal detection
logistic regression
url https://www.frontiersin.org/articles/10.3389/fcvm.2025.1504671/full
work_keys_str_mv AT jiazhenjiang adverseeventsassociatedwithamlodipineapharmacovigilancestudyusingthefdaadverseeventreportingsystem
AT qianzhong adverseeventsassociatedwithamlodipineapharmacovigilancestudyusingthefdaadverseeventreportingsystem
AT xinyuzhou adverseeventsassociatedwithamlodipineapharmacovigilancestudyusingthefdaadverseeventreportingsystem
AT lisizhou adverseeventsassociatedwithamlodipineapharmacovigilancestudyusingthefdaadverseeventreportingsystem
AT jiyuanzheng adverseeventsassociatedwithamlodipineapharmacovigilancestudyusingthefdaadverseeventreportingsystem
AT bingshuoliu adverseeventsassociatedwithamlodipineapharmacovigilancestudyusingthefdaadverseeventreportingsystem
AT xingweidi adverseeventsassociatedwithamlodipineapharmacovigilancestudyusingthefdaadverseeventreportingsystem